Cargando…

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors

Aims. Inhibitors of the MET pathway hold promise in the treatment for metastatic kidney cancer. Assessment of predictive biomarkers may be necessary for appropriate patient selection. Understanding MET expression in metastases and the correlation to the primary site is important, as distant tissue i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shuch, Brian, Falbo, Ryan, Parisi, Fabio, Adeniran, Adebowale, Kluger, Yuval, Kluger, Harriet M., Jilaveanu, Lucia B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584049/ https://www.ncbi.nlm.nih.gov/pubmed/26448928 http://dx.doi.org/10.1155/2015/192406

Ejemplares similares

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
por: Parisi, Fabio, et al.
Publicado: (2010)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
por: Kluger, Dan M., et al.
Publicado: (2020)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

VDA, a Method of Choosing a Better Algorithm with Fewer Validations
por: Strino, Francesco, et al.
Publicado: (2011)

MET Expression in Sporadic Renal Cell Carcinomas
por: Choi, Jong Sun, et al.
Publicado: (2006)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
por: Tran, Thuy T., et al.
Publicado: (2019)

Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
por: Tran, Thuy T., et al.
Publicado: (2021)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
por: Kim, Ha-Jeong, et al.
Publicado: (2016)

Characterizing disease states from topological properties of transcriptional regulatory networks
por: Tuck, David P, et al.
Publicado: (2006)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

TrAp: a tree approach for fingerprinting subclonal tumor composition
por: Strino, Francesco, et al.
Publicado: (2013)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

MetExtract II: A Software Suite for Stable Isotope-Assisted Untargeted Metabolomics
por: Bueschl, Christoph, et al.
Publicado: (2017)

c-Met expression in renal cell carcinoma with bone metastases
por: Silva Paiva, Rita, et al.
Publicado: (2020)

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
por: Rhoades Smith, Katherine Emilie, et al.
Publicado: (2019)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

MetExtract: a new software tool for the automated comprehensive extraction of metabolite-derived LC/MS signals in metabolomics research
por: Bueschl, Christoph, et al.
Publicado: (2012)

Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
por: Wang, Huimin, et al.
Publicado: (2015)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ra5do19kh1g0v4br4r6mdr2dso